<DOC>
	<DOCNO>NCT01661322</DOCNO>
	<brief_summary>The risk recurrence great immediately stroke Transient Ischaemic Attack ( TIA ) . Existing prevention strategy ( antithrombotic , lipid/blood pressure lowering , endarterectomy ) reduce , abolish , event . Dual antiplatelet therapy - aspirin &amp; clopidogrel ( AC ) IHD , aspirin &amp; dipyridamole ( AD ) stroke , superior aspirin monotherapy . The investigator hypothesise triple antiplatelet therapy ( ACD ) superior AD patient high-risk recurrence , provide bleed become excessive . Design : TARDIS multicentre , parallel-group , prospective , randomised , open-label , blinded-endpoint , controlled trial . In start-up phase , investigator assess 3 year safety , tolerability feasibility intensive therapy ( ACD ) versus guideline therapy ( AD ) give 1 month 750 patient acute stroke/TIA . The main phase ass safety efficacy ACD 3500 patient . The primary outcome ordinal stroke ( fatal/severe non-fatal/mild/TIA/none ) 90 day . Secondary outcome include death , MI , vascular event , function , bleeding , serious adverse event ; sub-studies ass cerebral embolus platelet function .</brief_summary>
	<brief_title>Triple Antiplatelets Reducing Dependency After Ischaemic Stroke</brief_title>
	<detailed_description>2.1 Purpose To perform randomised trial assess efficacy , safety tolerability intensive antiplatelet therapy ( Asp+Dip+Clop ) versus guideline antiplatelet therapy ( Asp+Dip Clop ) patient recent ischaemic stroke TIA high risk recurrence . 2.2 Primary Objective To assess ordinal stroke severity 90 day short-term administration ( 1 month ) intensive antiplatelet therapy versus guideline therapy patient recent ischaemic stroke TIA . 2.3 Secondary Objectives 1 . To assess safety short-term administration ( 1 month ) intensive antiplatelet therapy versus guideline therapy patient recent ischaemic stroke TIA . 2 . To assess , high risk patient stroke/TIA , whether : ii . feasible administer intensive therapy acutely tolerable take 1 month , iii . intensive therapy superior respect surrogate marker platelet function . iv . intensive therapy improve functional outcome</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Adults high risk recurrent ischaemic stroke : 1 . Age â‰¥ 50 year 2 . Within 48 hour ictus ( 2448 hour thrombolysed ) 3 . TIA limb weakness and/or dysphasia last 10 minute &lt; 24 hour residual symptom present follow ABCD2 score &gt; 4 , Crescendo TIA Already dual antiplatelet therapy Note : Neuroimaging necessary transient ischaemic attack . Crescendo TIA &gt; 1 TIA one week onset time last TIA take time ictus . 4 . Ischaemic non cardioembolic stroke present follow Ongoing limb weakness and/or dysphasia one hour duration Resolved limb weakness one hour duration ongoing facial weakness Ongoing isolate hemianopia 1 hour duration positive neuroimaging evidence support index event ( e.g . ischaemic stroke occipital lobe ) Resolved limb weakness and/or dysphasia 2448 hour index event onset Note : Neuroimaging essential ischaemic stroke exclude intracranial haemorrhage and/or non stroke diagnosis 5 . Informed consent participant . If participant unable give meaningful consent e.g . due dysphasia , confusion , reduce conscious level , proxy consent may obtain relative , carer legal representative . 1 . Age &lt; 50 2 . Isolated sensory symptom vertigo/dizziness facial weakness 3 . Isolated hemianopia without positive neuroimaging evidence 4 . Intracranial haemorrhage 5 . Baseline neuroimaging show parenchymal haemorrhagic transformation ( PH I/II ) infarct , subarachnoid haemorrhage non ischaemic cause symptom 6 . Presumed cardioembolic stroke ( e.g . history current AF , myocardial infarction within 3 month ) 7 . Participants contraindication , intolerance , aspirin , clopidogrel dipyridamole . 8 . Participants definite need treatment aspirin , clopidogrel dipyridamole individually combination ( e.g . aspirin clopidogrel recent MI/acute coronary syndrome ) 9 . Participant take clopidogrel dipyridamole index event prior randomisation ( aspirin allow ictus onset randomisation ) 10 . Definite need full dose oral ( e.g . warfarin , dabigatran ) medium high dose parenteral ( e.g . heparin ) anticoagulation . NB Low dose heparin DVT prophylaxis allow 11 . Definite need glycoprotein IIbIIIa inhibitor 12 . Received thrombolysis within last 24 hour 13 . No enteral access 14 . Premorbid dependency ( mRS &gt; 2 ) . 15 . Severe high BP ( BP &gt; 185/110 mmHg ) . 16 . Haemoglobin less 10g/dL 17 . Platelet count 600 x 109 /L less 100 x 109 /L 18 . White cell count 30 x 109 /L less 3.5 x 109 /L 19 . Major bleed within 1 year ( e.g . peptic ulcer , intracerebral haemorrhage ) . 20 . Planned surgery 3 month followup ( e.g . carotid endarterectomy ) 21 . Concomitant STEMI NSTEMI . 22 . Stroke secondary procedure ( e.g . carotid coronary intervention ) 23 . Coma ( GCS &lt; 8 ) 24 . Nonstroke life expectancy &lt; 6 month 25 . Dementia 26 . Participation another drug device trial concurrently within 30 day . ( participant may take part observational study nondrug device trial ) 27 . Geographical factor may interfere followup e.g . fixed address telephone contact number , register GP , overseas visitor . 28 . Females childbearing potential , pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute ischaemic stroke</keyword>
	<keyword>TIA</keyword>
</DOC>